Everyday Health15h
FDA Approves First Medication for Obstructive Sleep Apnea
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...
Psychology Today22h
GLP-1RAs in People With Higher Weight and Eating Disorders
GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...
FDA proposes rule to target asbestos in talc cosmetic products
The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...
FDA approves first generic liraglutide once-daily injection
The U.S. Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals) ...
From Hollywood's best-kept secret to affordable weight loss for all
GLP-1 medications like Semaglutide (found in Ozempic and Wegovy) and Tirzepatide (found in Mounjaro) mimic the body’s natural ...
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand Version
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
KSJB AM1d
Which State Medicaid Programs Cover GLP-1s for Weight Loss & How Much Are They Spending?
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...
Tyler Morning Telegraph1d
Medicaid Now Covers GLP-1s for Obesity in Texas
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Wyoming News1d
Wyoming Among Minority of States Where Medicaid Doesn't Cover Obesity-Indicated GLP-1s
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
The Mountaineer1d
North Carolina Medicaid Spend on GLP-1s for Obesity up 111% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
San Francisco Examiner1d
FDA Approves Generic GLP-1 Medicine For Diabetes Treatment
THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of ...
Becker's Hospital Review1d
The GLP-1 dilemma persists into 2025
MassHealth is transitioning coverage for anti-obesity drugs, designating Zepbound as the preferred option starting in January 2025, with Wegovy and Saxenda being discontinued for most adult members.